Diabetes drug may unlock kidney mineral mysteries in cystic disease

NCT ID NCT06435858

Recruiting now Knowledge-focused Sponsor: Cantonal Hospital Graubuenden Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 37 times

Summary

This study looks at how Empagliflozin, a diabetes drug, changes the way the kidneys handle calcium, phosphate, and magnesium in people with autosomal dominant polycystic kidney disease (ADPKD). About 40 adults will take either the drug or a placebo for 2 weeks, then switch after a 2-week break. The goal is to learn more about electrolyte balance, not to treat the disease directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cantonal Hospital Graubuenden
RECRUITING

Chur, Kanton Graubünden, 7000, Switzerland

Contact

Contact Email: •••••@•••••
University Hospital Zurich, Division of Nephrology
RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland

Contact

Conditions

Explore the condition pages connected to this study.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE